Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Oxidative Stress and Nutritional Supplementation Intervention Study (Oxi-Stress)

This study has been completed.
Sponsor:
Collaborator:
Saskatchewan Health Research Foundation
Information provided by (Responsible Party):
Susan Whiting, University of Saskatchewan
ClinicalTrials.gov Identifier:
NCT01234506
First received: November 2, 2010
Last updated: July 30, 2013
Last verified: July 2013

November 2, 2010
July 30, 2013
October 2010
July 2013   (final data collection date for primary outcome measure)
  • Safety of consumption of 300 mg/day of the flax lignan secoisolariciresinol diglucoside (SDG) in older adults (60-80 y) [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
    Adverse event occurrences will be compared descriptively between the SDG and placebo groups. Safety will be assessed at 0, 6, 12, 18 and 24 weeks; as part of the blood collection (urea, creatinine, total bilirubin, platelets, hematocrit, haemoglobin, mean corpuscular haemoglobin, mean corpuscular volume, white blood cell count, total protein including albumin and prealbumin, total calcium, electrolytes, glucose, liver enzymes (AST, ALT, ALP), total protein, albumin, lipids, HbA1c (for diabetic participants). Blood pressure measurements will be performed every two weeks
  • Effect of SDG on oxidative stress and inflammation [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    SDG and placebo groups will be compared at 0, 12 and 24 weeks for changes in oxidative stress measurements (plasma malondialdehyde), pro-inflammatory markers (IL-6, IL-1α, IL-1β, 8-isoprostane, TNF-α, C-reactive protein).
Same as current
Complete list of historical versions of study NCT01234506 on ClinicalTrials.gov Archive Site
  • Effect of SDG on quality of life [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    SDG and placebo groups will be compared at 0, 12 and 24 weeks for changes in cognitive function, pain, and physical function including falls, as well as performance of activities of daily living.
  • Effect of SDG supplement on blood levels of flax lignan metabolites [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    To further understand the pharmacology of SDG, we will analyze plasma levels of the SDG metabolites secoisolariciresinol, enterolactone and enterodiol in those subjects given flax lignan supplement. Levels will be determined 0, 12 and 24 weeks.
  • To measure effects of SDG on bone resorption [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    SDG and placebo groups will be compared at 0 and 24 weeks for changes in bone resorption as assessed by measurement of cross-linked N-telopeptides type I collagen serum levels.
  • Effect of SDG on blood lipids [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    SDG and placebo groups will be compared at 0, 12 and 24 weeks for changes in nonfasting levels of cholesterol, LDL, HDL, and triglycerides.
  • Effect of SDG on quality of life [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    SDG and placebo groups will be compared at 0, 12 and 24 weeks for changes in cognitive function, pain, and physical function including falls, as well as performance of activities of daily living.
  • Effect of SDG supplement on blood levels of flax lignan metabolites [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    To further understand the pharmacology of SDG, we will analyze plasma levels of the SDG metabolites secoisolariciresinol, enterolactone and enterodiol in those subjects given flax lignan supplement. Levels will be determined 0, 12 and 24 weeks.
  • To measure effects of SDG on bone resorption [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    SDG and placebo groups will be compared at 0 and 24 weeks for changes in bone resorption as assessed by measurement of cross-linked N-telopeptides type I collagen serum levels.
  • Effect of SDG on blood lipids [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    SDG and placebo groups will be compared at 0, 12 and 24 weeks for changes in nonfasting levels of cholesterol, LDL, HDL, and triglyciderides.
Not Provided
Not Provided
 
Oxidative Stress and Nutritional Supplementation Intervention Study
Community Alliance for Quality of Life in Long Term Care: Oxidative Stress and Nutritional Supplementation Intervention Study

A major means whereby oxidative stress promotes aging-related disease is by activating inflammatory pathways. Decreasing oxidative stress and inflammation should ameliorate many of the problems associated with aging, including vascular dementia, Alzheimer's disease, osteoporosis, muscle wasting, insulin resistance, type 2 diabetes, and metabolic syndrome. Animal and human studies have demonstrated that consumption of vitamin D and phase 2 protein inducers decrease oxidative stress and associated inflammation. The flax lignan secoisolariciresinol diglucoside (SDG) is metabolized to enterolactone, a potent phase 2 protein inducer. Animal and human studies have shown that consumption of flax seed or its component SDG decreases hypertension, serum cholesterol, atherosclerosis, the growth of experimentally-induced cancers as well as metastases of human breast tumours implanted into nude mice, and delays the development of type 2 diabetes. Vitamin D plays a role in modulating inflammation, enhancing immunity (while suppressing autoimmune injury) and exerting control over cell differentiation. Adequate levels of vitamin D also appear to promote better glycemic control. The investigators predict that consumption of SDG in persons with adequate vitamin D status will decrease oxidative stress and associated inflammation. If this hypothesis is upheld, this research has the potential to greatly decrease healthcare costs while allowing healthier aging.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Oxidative Stress
  • Inflammation
  • Aging
  • Dementia
  • Pain
Dietary Supplement: secoisolariciresinol diglucoside
SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
Other Names:
  • Beneflax Flax Lignan Extract Archer Daniels Midland,#080001.
  • Natural Factors Whey Factors whey protein (unflavored).
  • Vitamin D NPN 80003663 WN Pharmaceuticals
  • Active Comparator: secoisolariciresinol diglucoside
    Secoisolariciresinol diglucoside (SDG) supplementation as 0.8g/day of BeneFlax containing 300 mg SDG. 1000 IU vitamin D as standard of care.
    Intervention: Dietary Supplement: secoisolariciresinol diglucoside
  • Placebo Comparator: Placebo
    An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
    Intervention: Dietary Supplement: secoisolariciresinol diglucoside
Adolphe JL, Whiting SJ, Juurlink BH, Thorpe LU, Alcorn J. Health effects with consumption of the flax lignan secoisolariciresinol diglucoside. Br J Nutr. 2010 Apr;103(7):929-38. doi: 10.1017/S0007114509992753. Epub 2009 Dec 15. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21
July 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • adults residing in a long term care facility
  • resident for a minimum of four weeks prior to entry
  • able to comply with study protocol
  • able to follow simple instructions
  • able to give informed consent or has a legally acceptable representative who is able to provide consent

Exclusion Criteria:

  • Age below 60 or above 80 years.
  • Individuals at risk of hypotension or with symptomatic hypotension.
  • Fasting hypoglycemia.
  • Unstable diabetes
  • Diabetics taking insulin
  • Current cancer or diagnosed with cancer in the past 2 years.
  • Women with an immediate family history or personal history of breast cancer or ovarian cancer
  • Significant liver disorder
  • Significant gastrointestinal disorder including inflammatory bowel disease but not constipation
  • Significant kidney disorder
  • Unstable or severe cardiac disease, recent MI or stroke either in past 6 months or significantly (i.e., severely) affecting physical mobility.
  • Unstable other medical disease including, but not limited to, pulmonary disorder, epilepsy and genitourinary disorder.
  • Migraine with aura within the last year (as this is a risk factor for stroke).
  • Current diagnosis of a bleeding condition, or at risk of bleeding.
  • Significant immunocompromise.
  • Other unstable conditions.
  • Current use of hormone replacement therapy except thyroid medication
  • Current use of warfarin, clopidogrel, ticlopidine, dipyridamole or their analogues.
  • Intolerances or allergies to flax or vitamin D.
  • Estimated probability of longevity of less than one year based on medical opinion
Both
60 Years to 80 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01234506
NHPD-150212
No
Susan Whiting, University of Saskatchewan
University of Saskatchewan
Saskatchewan Health Research Foundation
Principal Investigator: Susan J Whiting, PhD University of Saskatchewan
University of Saskatchewan
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP